九洲药业(603456.SH)：收到化学原料药上市申请批准通知书

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) has received approval from the National Medical Products Administration for the marketing application of Citric Acid Tianeptine, an anti-anxiety medication used for various anxiety states caused by neuroses, such as generalized anxiety disorder, and anxiety states associated with primary hypertension and peptic ulcers [1]. Group 1 - The company has been granted a marketing approval notice for Citric Acid Tianeptine, with the notification number 2026YS00030 [1]. - Citric Acid Tianeptine is primarily indicated for treating anxiety states resulting from various neuroses [1]. - The medication is also applicable for anxiety states associated with physical conditions such as primary hypertension and peptic ulcers [1].